<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-2395</journal-id>
<journal-title><![CDATA[Revista da Sociedade Portuguesa de Dermatologia e Venereologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Soc Port Dermatol Venereol]]></abbrev-journal-title>
<issn>2182-2395</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Dermatologia e Venereologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-23952021000400021</article-id>
<article-id pub-id-type="doi">10.29021/spdv.79.4.1450</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Determinantes do Tempo de Sobrevivência do Metotrexato na Psoríase: Análise Retrospetiva de 10 Anos do Registo DERMA.PT]]></article-title>
<article-title xml:lang="en"><![CDATA[Determinants for Drug Survival of Methotrexate in Patients with Psoriasis: 10-Years Retrospective Analysis of DERMA.PT Registry]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[Nuno]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[Camila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[Filomena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Magin]]></surname>
<given-names><![CDATA[Sofia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar Universitário de São João (CHUSJ) Serviço de Dermatologia e Venereologia ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade do Porto Faculdade de Medicina ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,CINTESIS - Centro de Investigação em Tecnologias e em Serviços de Saúde  ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>79</volume>
<numero>4</numero>
<fpage>21</fpage>
<lpage>29</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-23952021000400021&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-23952021000400021&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-23952021000400021&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  O metotrexato é utilizado no tratamento sistémico da psoríase desde 1950, continuando a ser um fármaco de primeira linha. É importante avaliar os fatores que influenciam a sua descontinuação. O objetivo dos autores foi identificar determinantes do tempo de sobrevivência do metotrexato em doentes com psoríase.  Métodos: Foi realizada uma análise retrospetiva dos doentes incluídos no registo nacional DERMA.PT pelo Centro Hospitalar Universitário São João e que iniciaram tratamento para a psoríase com metotrexato entre janeiro de 2010 e janeiro de 2020.  Resultados:  Foram identificados 146 doentes com psoríase tratados com metotrexato em monoterapia ou em associação com fototerapia. A maioria era do sexo masculino (55%), com idade média de 51±13 anos e com psoríase há mais de 10 anos. A psoríase vulgar (49%) e a psoríase artropática (47%) foram as formas mais comuns de psoríase, com um PASI inicial médio de 10,7±5,6. A maioria dos doentes era naïve para o tratamento com metotrexato. No total, 66 (45%) doentes descontinuaram o tratamento, com um tempo médio de sobrevivência do fármaco de 18,0±15,5 meses. As razões mais comuns de descontinuação foram ineficácia (32%), má adesão terapêutica (18%) e intolerância gastrointestinal (11%). O tratamento prévio com ciclosporina e a presença de artrite psoriática associaram-se ambos à descontinuação do metotrexato (estatisticamente significativo). Na maioria dos casos, foi realizado switch para anticorpo monoclonal anti-TNF&#945;.  Discussão:  Nos últimos anos, foram publicados estudos retrospetivos com enfoque no tempo de sobrevivência do metotrexato na psoríase, que revelaram um tempo médio entre 12 a 21 meses. As principais razões de descontinuação foram a ineficácia e os efeitos adversos, nomeadamente gastrointestinais. O nosso estudo está em linha com o descrito mas destaca-se pela elevada percentagem de doentes que mantiveram o tratamento. A tremenda evolução no tratamento da psoríase ao longo dos 10 anos do estudo influenciou grandemente os resultados. A principal limitação desta análise resulta do facto de ser um estudo retrospetivo.  Conclusão:  Os resultados estão de acordo com as caraterísticas de sobrevivência do metotrexato publicadas e reforçam a sua importância e o seu papel no tratamento desta doença.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT   Introduction:  Methotrexate has been used in the systemic treatment of psoriasis since 1950 and remains a first-line drug. It is important to assess the factors that influence its discontinuation. The aim of the authors was to identify determinants of drug survival of metho-trexate in patients with psoriasis.  Methods:  A retrospective analysis was performed concerning patients who started psoriasis treatment with methotrexate between January 2010 and January 2020 and were included in the national registry DERMA.PT by the Centro Hospitalar Universitário São João.  Results:  A total of 146 patients with psoriasis treated with methotrexate alone or in combination with phototherapy were identified. Most were male (55%), with a mean age of 51±13 years and 65% had psoriasis for more than 10 years. Psoriasis vulgaris (49%) and psoriatic arthritis (47%) were the most common forms of psoriasis, with a mean initial PASI of 10.7±5.6. The majority of patients were methotrexate-naïve. In total, 66 (45%) patients discontinued treatment, with a mean survival time of 18.0±15.5 months. The most common reasons for discontinuation were ineffectiveness (32%), poor compliance (18%) and gastrointestinal intolerance (11%). Previous treatment with cyclosporine and the presence of psoriatic arthritis had both statistically significant associations with the discontinuation of methotrexate. In most cases, a switch to anti-TNF&#945; monoclonal antibody was performed.  Discussion:  In recent years, retrospective studies have been published focusing on the drug survival of methotrexate in psoriasis, ranging from 12 to 21 months. The main reasons for discontinuation were ineffectiveness and adverse effects, namely gastrointestinal. Our study is in line with what has been described but stands out for the high percentage of patients who maintained treatment. The tremendous evolution in the treatment of psoriasis over the 10-year period of the study greatly influenced the results. The main limitation of this analysis results from its retrospective nature.  Conclusion:  The results are in agreement with the published survival characteristics of methotrexate and reinforce its importance and role of this drug in the treatment of this disease.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Metotrexato/uso terapêutico]]></kwd>
<kwd lng="pt"><![CDATA[Portugal]]></kwd>
<kwd lng="pt"><![CDATA[Psoríase/tratamento]]></kwd>
<kwd lng="pt"><![CDATA[Registos.]]></kwd>
<kwd lng="en"><![CDATA[Methotrexate/therapeutic use]]></kwd>
<kwd lng="en"><![CDATA[Portugal]]></kwd>
<kwd lng="en"><![CDATA[Psoriasis/therapy]]></kwd>
<kwd lng="en"><![CDATA[Registries.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Wehausen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment Changes in Patients With Moderate to Severe Psoriasis A Retrospective Chart Review]]></article-title>
<source><![CDATA[J Cutan Med Surg]]></source>
<year>2018</year>
<volume>22</volume>
<page-range>25-30</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Due]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Blomberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Skov]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zachariae]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discontinuation of methotrexate in psoriasis]]></article-title>
<source><![CDATA[Acta Derm Venereol]]></source>
<year>2012</year>
<volume>92</volume>
<page-range>353-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Gottlieb]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Au]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies]]></article-title>
<source><![CDATA[J Drugs Dermatol]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>848-53</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dogra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mahajan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic methotrexate therapy for psoriasis past, present and future]]></article-title>
<source><![CDATA[Clin Exp Dermatol]]></source>
<year>2013</year>
<volume>38</volume>
<page-range>573-88</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Be-liefs About Medicines in Patients with Psoriasis Treated with Methotrexate or Bio-logics A Cross-sectional Survey Study]]></article-title>
<collab>van den Reek PA.van de Kerkhof CM.Mertens JS.Seyger MB.Kievit W</collab>
<source><![CDATA[Acta Derm Venereol]]></source>
<year>2019</year>
<volume>99</volume>
<page-range>386-92</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marco]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vincenzo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gianfranco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methotrexate practical use in dermatology]]></article-title>
<source><![CDATA[G Ital Dermatol Venereol]]></source>
<year>2016</year>
<volume>151</volume>
<page-range>535-43</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elmamoun]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chandran]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of Methotrexate in the Management of Psoriatic Arthritis]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2018</year>
<volume>78</volume>
<page-range>611-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Gossec]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ramiro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mease]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New GRA-PPA and EULAR recommendations for the management of psoriatic arthritis]]></article-title>
<collab>van der Heijde D.Smolen JS</collab>
<source><![CDATA[Rheumatology]]></source>
<year>2017</year>
<volume>56</volume>
<page-range>1251-3</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinants for drug survival of methotrexate in patients with psoriasis, split according to di-fferent reasons for discontinuation results of the prospective MTX-CAPTURE]]></article-title>
<collab>van den Reek JM.Seyger MM.van de Kerkhof PC.Kievit W.de Jong EM</collab>
<source><![CDATA[Br J Dermatol]]></source>
<year>2017</year>
<volume>177</volume>
<page-range>497-504</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yiu]]></surname>
<given-names><![CDATA[ZN]]></given-names>
</name>
<name>
<surname><![CDATA[McElhone]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ashcroft]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Kleyn]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults a sys-tematic review.]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2019</year>
<volume>181</volume>
<page-range>256-64</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dávila-Seijo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dauden]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Carretero]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrandiz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vanaclocha]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-García]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival of classic and biological systemic drugs in psoriasis results of the BIOBADA-DERM reg-istry and critical analysis]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2016</year>
<volume>30</volume>
<page-range>1942-50</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shalom]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zisman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Harman-Boehm]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Biterman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg-Dotan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Polishchuk]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis]]></article-title>
<source><![CDATA[Acta Derm Venereol]]></source>
<year>2015</year>
<volume>95</volume>
<page-range>973-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wojciech]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aleksandra]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Magdalena]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Andrzej]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jacek]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Folate supplementation re-duces the side effects of methotrexate therapy for psoriasis]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>1015-21</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cline]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jorizzo]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does daily folic acid supplementation reduce methotrexate efficacy?]]></article-title>
<source><![CDATA[Dermatol Online J]]></source>
<year>2017</year>
<volume>15</volume>
<page-range>23</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Busard Cl]]></surname>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gkalpakiotis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cazzaniga]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Stern]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis real-life data from PSONET registries]]></article-title>
<source><![CDATA[J Eur Acad Dermatol Venereol]]></source>
<year>2018</year>
<volume>32</volume>
<page-range>245-53</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maul]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Djamei]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kolios]]></surname>
<given-names><![CDATA[AGA]]></given-names>
</name>
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Czernielewski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jungo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and survival of systemic psoriasis treatments an analysis of the Swiss registry SDNTT]]></article-title>
<source><![CDATA[Dermatology]]></source>
<year>2016</year>
<volume>232</volume>
<page-range>640-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schaarschmidt]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Herr]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Goerdt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Peitsch]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug survival rates and reasons for drug discontinuation in psoriasis]]></article-title>
<source><![CDATA[J Dtsch Dermatol Ges]]></source>
<year>2016</year>
<volume>14</volume>
<page-range>1089-99</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mrowietz]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Elder]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Barker]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The importance of disease associations and concomi-tant ther-apy for the long-term management of psoriasis patients]]></article-title>
<source><![CDATA[Arch Dermatol Res]]></source>
<year>2006</year>
<volume>298</volume>
<page-range>309-19</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bronckers]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Paller]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[West]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Lara-Corrales]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tollefson]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents]]></article-title>
<collab>Tom WL et al</collab>
<source><![CDATA[JAMA Dermatol]]></source>
<year>2020</year>
<volume>156</volume>
<page-range>384-92</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vollenbroek]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<name>
<surname><![CDATA[Doggen]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Janssens]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Moens]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guideli-nes]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2018</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shivani]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Mark]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psoriasis Which therapy for which patient: Focus on special popu-la-tions and chronic infections]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2019</year>
<volume>80</volume>
<page-range>43-53</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Strober]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Kivelevitch]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Prater]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Stoff]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Joint AAD-NPF gui-delines of care for the management and treatment of psoriasis with biologics]]></article-title>
<source><![CDATA[J Am Acad Der-matol]]></source>
<year>2019</year>
<volume>80</volume>
<page-range>1029-72</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
